Monoethanolamine

Monoethanolamine

SCHEMBL3230998

Cc1ccc(OCc2ccc(-c3ccc(C(F)(F)F)cc3)cc2C)c(-c2csc(N3CCC(C(=O)O)CC3)n2)c1.NCCO

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MPL

The experimentally established mechanism targets of Monoethanolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
GUCY1B2 O75343 19/20 0.45
GUCY1A2 P33402 19/20 0.45
GUCY1A1 Q02108 19/20 0.45
GUCY1B1 Q02153 19/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3228958 0.96 GUCY1B2 (0.48) GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPC1
SCHEMBL3231428 0.90 NPC1 (0.43) GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPC1
SCHEMBL3234405 0.90 NPC1 (0.43) GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPC1
SCHEMBL3234333 0.90 NPC1 (0.45) GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPC1
Monoethanolamine SCHEMBL3239701 0.89 GUCY1B2 (0.45) GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPC1
SCHEMBL14952879 0.88 GUCY1B2 (0.46) GUCY1B2GUCY1A2GUCY1A1GUCY1B1
SCHEMBL3236272 0.88 GUCY1B2 (0.45) GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPC1
SCHEMBL3225181 0.88 GUCY1B2 (0.42) GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPC1
SCHEMBL3233253 0.88 RAB9A (0.47) GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPC1
SCHEMBL3230171 0.88 L3MBTL1 (0.46) GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594270-A2 The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) BIP Patents (DE) 2013-05-22 EP claimed
EP-2594270-A2 The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) BIP Patents (DE) 2013-05-22 EP disclosed
WO-2010015652-A2 THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE SMITHKLINE BEECHAM CORPORATION (US) 2010-02-11 WO disclosed